RARE MAPS · Dynamic proteomic maps of stem cell-derived neurons as a mechanistic discovery pipeline for rare neurological disease
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-02-01 → 2023-01-31
- Финансиране от ЕС
- 162 806 €
- Участници
- 1
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Невронни клетки, създадени от стволови клетки, се анализират чрез протеомни карти, за да се види как се променят протеините при редки неврологични заболявания. Това помага за разбирането на механизмите на тези болести на клетно ниво, което е трудно поради недостъпността на нервната система.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Dynamic proteomic maps of stem cell-derived neurons as a mechanistic discovery pipeline for rare neurological disease
‘RARE MAPS’ aimed to address the challenge of investigating disease mechanisms for rare genetic neurological disorders. In Europe, rare diseases are those that affect less than 1 in 2000 people. However, the existence of up to 8000 different rare (mostly genetic) diseases means that collectively they are anything but rare; around 30 million people are estimated to suffer from a rare disease in Europe alone. This creates a huge medical burden, as most rare diseases have no known effective treatment. The bottleneck in developing targeted therapies is in understanding the underlying mechanisms of diseases at a cellular level. This is particularly challenging for neurological diseases, because the affected tissue (the nervous system) is inaccessible and difficult to model in the lab. Thus, it is important to develop new approaches to systematically study rare disease pathology. The overarching goal of RARE MAPS is to develop a mechanistic discovery pipeline that can be widely applied to rare neurological disorders. To do this, RARE MAPS proposed to combine disease modelling using human induced pluripotent stem cells (hiPSCs) with a spatial proteomics method called ‘Dynamic Organellar Maps’ (DOMs), to understand how proteins within neurons are altered during disease. hiPSCs are cells that can differentiate into any cell type of the human body, including neurons. Gene editing technology can be used to introduce genetic mutations into hiPSCs, which can then be differentiated into neurons, providing a model of neurological disease in a dish. The DOMs method is then applied to reveal differences between healthy and diseased neurons, by providing information on the identity, quantity and localisation of proteins within the cell. Protein localisation is critical for protein function; cells consist of different membrane-bound compartments called organelles and proteins must be in the correct place to perform their function. Protein trafficking pathways make sure that proteins get to the right destinations. The importance of these pathways is highlighted by the fact that common neurological diseases, e.g., Parkinson’s disease, involve defects in protein trafficking. Many rare genetic neurological disorders are also caused by problems with protein trafficking, for example, the childhood neurodegenerative disease, AP-4 deficiency syndrome. AP-4 deficiency syndrome is a form of hereditary spastic paraplegia, caused by mutations in a set of genes that create a protein complex called AP-4, which is required for protein trafficking. Using AP-4 deficiency syndrome as a test-case, the main objectives of RARE MAPS were: 1) to establish the DOMs approach in hiPSC-derived neurons; 2) to apply DOMs to study protein trafficking defects in whole brain tissue; 3) to investigate the mechanisms leading to AP-4 deficiency syndrome. The action was successful in meeting its objectives, leading both to the development of methods that can be widely used to study neurological disease, as well as to an increased understanding of the protein mislocalisation events that contribute to disease caused by AP-4 deficiency.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Rare diseases are a major unmet medical need, as is the definition of the relevant disease mechanisms. Many rare diseases affect the nervous system. These are challenging to treat, and mechanistic studies are difficult due to the inaccessibility of patient tissue. Global proteomic studies have provided insight into whole tissue or cell changes in protein abundance but lose information on protein subcellular localisation, which is important because defects in protein trafficking are implicated in many neurological disorders. In ‘RARE MAPS’ I propose an unbiased mechanistic discovery pipeline combining human induced pluripotent stem cells (hiPSCs) with advanced spatial proteomics. I will use a method developed by Dr. Borner called ‘dynamic organellar maps’, which provides quantitative protein subcellular localisation information at the whole proteome level. Used comparatively, it can detect changes in protein localisation due to a perturbation, allowing unbiased screening for phenotypic changes. To develop this workflow, I will apply it to the rare neurodegenerative disorder AP-4 deficiency syndrome. AP-4 knockout hiPSCs will be differentiated into cortical neurons and maps will be made of intermediate cortical stem cells and mature cortical neurons. Comparison to control cells will enable the detection of changes to protein localisation and abundance. I will also apply the maps to brain tissue from an AP-4 deficient mouse model to detect protein mislocalisation in vivo. I will then use CRISPR/Cas9 technology to investigate the role of novel and known AP-4-associated proteins in neuronal autophagy and axonal health. This project will demonstrate the utility of dynamic organellar maps to reveal molecular mechanisms of rare neurological disorders as well as provide new insights into the pathogenesis of AP-4 deficiency and the role of protein trafficking and autophagy in the axon.
Оригинален текст от CORDIS (на английски).
Участници
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENКоординаторГермания
Връзки
Данни: CORDIS, © Европейски съюз
